10th Oct 2019 12:43
(Alliance News) - Hutchison China Meditech Ltd on Thursday said it has expanded its collaboration agreement with Innovent Biologics Inc to evaluate the safety and efficacy of Tyvyt.
Tyvyt, an injection of sintilimab, is Innovent's human anti-programmed cell death protein 1 monoclonal antibody.
The expansion of the collaboration will allow Innovent and Hutchison to jointly explore the potential application of Tyvyt and Hutchison's surufatinib combination therapy in solid tumours with global unmet medical needs.
The combination of Tyvyt and surufatinib is expected to have synergistic anti-tumour effects by simultaneously targeting multiple cell types and signalling pathways in the tumour micro-environment, said Hutchison.
Clinical studies with this new combination will be conducted both in the US and in China, Hutchison added. Preclinical studies, meanwhile, have suggested surufatinib is able to inhibit angiogenesis, block the accumulation of tumour associated macrophages and promote infiltration of effector T cells into tumours, all of which could contribute to improve anti-tumour activity of Tyvyt.
"We are excited to further collaborate with Hutchison to develop the combination therapy of sintilimab and surufatinib, hoping more patients will benefit from this potential therapy globally," said Michael Yu, chair & chief executive of Innovent.
"We believe the future of oncology treatments increasingly lies in combining therapies, utilizing multiple mechanisms of action to greatly improve the treatment of solid tumours," said Christian Hogg, chief executive of Hutchison.
Hutchison shares were trading 2.7% lower on Thursday in London at 280.00 pence each.
By Evelina Grecenko; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed